Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Iomab-B (I-131-apamistamab)
i
Other names:
BC8-I-131 construct, 131-I-labeled BC8 antibody, BC 8, anti-CD45 monoclonal antibody-BC8-I-131
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Actinium, Immedica
Drug class:
Alpha radiation emitter, CD45-targeted antibody- radioimmunoconjugate conjugate
Related drugs:
‹
Ac-225 ErbB3 targeted radiotherapy (4)
lintuzumab-Ac225 (4)
RYZ101 (2)
radium Ra-223 dichloride (2)
ORM-2110 (1)
BAY2701439 (1)
Undisclosed EGFRvIII-targeted alpha therapy (1)
211At-OKT10-B10 (0)
212Pb-DOTAM-GRPR1 (0)
AAA817 (0)
AB001 (0)
CONV01-α (0)
FPI-1434 (0)
FPI-1966 (0)
FPI-2265 (0)
Iomab-ACT (0)
JNJ-6420 (0)
VMT-01 (0)
VMT-𝛼-NET (0)
[²¹¹At]PTT (0)
BAY 2315497 (0)
BAY 2287411 (0)
Ac-225 ErbB3 targeted radiotherapy (4)
lintuzumab-Ac225 (4)
RYZ101 (2)
radium Ra-223 dichloride (2)
ORM-2110 (1)
BAY2701439 (1)
Undisclosed EGFRvIII-targeted alpha therapy (1)
211At-OKT10-B10 (0)
212Pb-DOTAM-GRPR1 (0)
AAA817 (0)
AB001 (0)
CONV01-α (0)
FPI-1434 (0)
FPI-1966 (0)
FPI-2265 (0)
Iomab-ACT (0)
JNJ-6420 (0)
VMT-01 (0)
VMT-𝛼-NET (0)
[²¹¹At]PTT (0)
BAY 2315497 (0)
BAY 2287411 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
TP53 mutation
Acute Myelogenous Leukemia
TP53 mutation
Acute Myelogenous Leukemia
I-131-apamistamab
Sensitive: C3 – Early Trials
I-131-apamistamab
Sensitive
:
C3
I-131-apamistamab
Sensitive: C3 – Early Trials
I-131-apamistamab
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login